

# HIV and Gestation: Antenatal Care

Elie Nkwabong\*

Department of Obstetrics & Gynecology, University of Yaounde, Cameroon

## Antenatal care

### Prevention of mama-to-child transmission

The threat of HIV transmission from mama to child is most directly related to the viral load of the mama. Undressed mothers with a high (HIV RNA greater than 1000 copies/mL) have a transmission threat of over 50. For women with a lower viral load (HIV RNA lower than 1000 copies/mL), the threat of transmission is lower than 1.

### Ultramodern day antiretroviral remedy

All pregnant women who test positive for HIV should begin and continue ART regardless of CD4 counts or viral load to reduce the threat of viral transmission. Antiretroviral therapy is most importantly used at the following times in gestation to reduce the threat of mama-to-child transmission of HIV. During gestation pregnant women infected with HIV should have an oral therapy of at least three different anti-HIV specific drugs. During labor and delivery pregnant women infected with HIV who are formerly on triad ART should continue with their oral regimen. However, copies/mL, or there's question about whether specific drugs have been taken constantly, if their viral load is high (HIV RNA greater than 1). According to current recommendations by the WHO, CDC and U.S Department of Health and Human Services (DHHS), all individuals with HIV should begin ART as soon as they're diagnosed with HIV. The recommendation is stronger in the following situations

- CD4 count below 350 cells/ mm<sup>3</sup>
- High viral load (HIV RNA greater than 1000 copies/ mL)
- Progression of HIV to AIDS
- Development of HIV- related infections and ailments
- Gestation

### Labor and delivery

Women should continue taking their ART therapy on schedule and as specified throughout both the antenatal period and parturition. The viral load helps determine which mode of delivery is safest for both the mama and the baby [1].

According to the NIH, when the mama has been entering ART and her viral load is low (HIV RNA lower than 1000 copies/ mL) at the time of delivery, the threat of viral transmission during parturition is veritably low and a vaginal delivery may be performed. A cesarean delivery or induction of labor should only be performed in this patient population if they're medically necessary for non-HIV-related reasons [2].

Advances in HIV research, prevention, and treatment have made it possible for many women with HIV to give birth to babies who are free of HIV. The annual number of HIV infections through perinatal transmission in the United States and dependent areas has declined by more than 95% since the early 1990s [3].

The recommendation from 1985 that individuals in the U.S with HIV should be advised not to breastfeed remains consistent

with the most up-to-date scientific literature and is considered best practice for preventing HIV transmission. When resources exist that provide supplemental information related to this topic of the archived guideline, CDC may refer readers to other organizations. For example, the HHS Panel on treatment of HIV during Pregnancy and Prevention of Perinatal Transmission external icon and the American Academy of Pediatrics external icon have each more recently published recommendations on perinatal HIV prevention that are consistent with CDC's recommendation, but offer additional information for care providers of individuals with HIV who wish to breastfeed [4].

All women who present to the sanitarium in labor and their HIV status is unknown or they're at high threat of contracting an HIV infection but haven't entered repeat third trimester testing should be tested for HIV using a rapid-fire HIV antigen/ antibody test. However, Intra Venous (IV) Zidovudine should be initiated in the mama incontinently and further confirmational testing should be performed, if the rapid-fire testing is positive [5].

IV Zidovudine is an antiretroviral medicine that should be administered to women at or near the time of delivery in the following situations.

High viral load (HIV RNA greater than 1000 copies/mL)

- Unknown viral load
- Clinical doubt for maternal resistance with antenatal ART therapy
- Positive rapid-fire HIV antigen/ antibody test at labor or previous to a listed cesarean delivery

Administration of IV Zidovudine can be considered on a case-by-case basis for women who have a moderate viral load (HIV RNA greater than or equal to 50 copies/ mL AND lower than 1000 copies/ mL) near the time of delivery. IV Zidovudine is only not administered if women are both compliant with their specified ART therapy throughout gestation and have maintained a low viral load near the time of delivery (HIV RNA lower than 50 copies/ mL between 34-36 weeks gravidity) [6, 7].

Further considerations for managing HIV positive women during labor and delivery include the ensuing recommendations to reduce the threat of HIV transmission

\*Corresponding author: Elie Nkwabong, Department of Obstetrics & Gynecology, University of Yaounde, Cameroon, E-mail: elie.nkwabong@edu.cr

Received: 5-Feb-2022, Manuscript No: jpch-22-55756, Editor assigned: 7-Feb-2022, PreQC No: jpch-22-55756 (PQ), Reviewed: 14-Feb-2022, QC No: jpch-22-55756, Revised: 18-Feb-2022, Manuscript No: jpch-22-55756 (R), Published: 25-Feb-2022, DOI: 10.4172/2376-127X.1000518

Citation: Nkwabong E (2022) HIV and Gestation: Antenatal Care. J Preg Child Health 9: 518.

Copyright: © 2021 Nkwabong E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

- Avoid fetal crown electrodes for fetal monitoring, particularly if the motherly viral cargo is lesser than 50 clones/ mL.
- Avoid artificial rupture of membranes and operative vaginal delivery (using forceps or a vacuum extractor) if at all possible, particularly in women who haven't achieved viral suppression. However, they should be conducted precisely and following obstetric norms, if these styles need to be employed.
- The implicit relations between the specific ART medicines taken by the mama and those administered during labor should be considered by healthcare providers previous to medicine administration [8-10].

#### References

1. Tarimo CS (2019) Prevalence and predictors of failure in labor induction among pregnant women delivered in Northern-Tanzania 2000-2015: A Registry-based Retrospective Cohort Study. *Tanzan Med J* 30: 13-36.
2. Lyndrup J, Legarth J, Weber T, Nickelsen C, Guldbæk E (1992) Predictive value of pelvic scores for induction of labor by local PGE<sub>2</sub>. *Eur J Obstet Gynecol Reprod Biol* 47: 17-23.
3. Khan NB, Ahmed I, Malik A, Sheikh L (2012) Factors associated with failed induction of labour in a secondary care hospital. *J Pak Med Assoc* 62: 6.
4. Tripathy P, Pati T, Baby P, Mohapatra SK (2016) Prevalence and predictors of failed. *Int J Pharm Sci Rev Res* 39: 189-94.
5. Mbukani R, Kakoma J (2012) Is Nulliparity A Risk Factor For Poor Obstetrical And Neonatal Outcomes In Rwandan District Hospitals? A Prospective Observational Study at Muhima District Hospital. *Rwanda Med J* 69: 50-53.
6. Heffner LJ, Elkin E, Fretts RC (2003) Impact of labor induction, gestational age, and maternal age on cesarean delivery rates. *Obstet Gynecol* 102: 287-293.
7. Verhoeven CJ, Van Uytrecht CT, Porath MM, Mol BWJ (2013) Risk factors for caesarean delivery following labor induction in multiparous women. *J Pregnancy* 2013: 820892.
8. Hannah ME (1993) Post term pregnancy: should all women have labour induced ? A review of the literature. *Fetal Matern Med Rev* 5: 3-17.
9. Galal M, Symonds I, Murray H, Petraglia F, Smith R (2012) Post term pregnancy. *Facts, Views & Vis Obstet Gyn* 4: 175.
10. Obstetricians ACo, Gynecologists (2009) ACOG practice bulletin no. 107: Induction of labor. *Obstet Gynecol* 114: 386-397.